Seres Therapeutics (MCRB) Stock Declines in Second Day of Trading

NEW YORK (TheStreet) -- Seres Therapeutics (MCRB) shares closed trading down 25.70% to $38.19 in the second day of trading since the company's upsized initial public offering on Friday.

The Cambridge, MA-based company priced its upsized public offering of 7.43 million shares at $18 per share on Friday before closing trading up 68% to $50.49.

The company had previously said that it would offer 6.25 million shares between the $15 and $17 per share range.

Seres Therapeutics' lead development candidate, SER-109, is an oral therapeutic for the prevention of Clostridium difficile infection which affects between 85,000 and 110,000 people in the U.S.

The drug candidate is currently in Phase II trials.

MCRB Price Chart MCRB Price data by YCharts

More from Markets

Carnival CEO Arnold Donald: China Will Become the Largest Cruise Market

Carnival CEO Arnold Donald: China Will Become the Largest Cruise Market

Red Robin Slumps After Earnings Miss

Red Robin Slumps After Earnings Miss

Owner of Moviepass Sees Stock Plummet

Owner of Moviepass Sees Stock Plummet

Tiffany & Co. Sees a Strong Market in Asia

Tiffany & Co. Sees a Strong Market in Asia

Stocks Finish Higher After Release of Fed Minutes

Stocks Finish Higher After Release of Fed Minutes